Evommune, Inc. AI Stock Analysis
Want to see EVMN full AI Analyst Report?
Evommune, Inc. (EVMN) AI Stock Analysis
Evommune, Inc.
(NYSE:EVMN)
The score is held back primarily by weak financial performance (no TTM revenue, large losses, and substantial cash burn). Offsetting factors include a significantly improved balance sheet with low leverage and mixed-but-notable pipeline developments (positive EVO301 Phase 2a data tempered by EVO756 AD failure), while technicals show improving near-term momentum but remain stretched and below longer-term trend averages.
Evommune, Inc. (EVMN) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $291.06M
- Dividend Yield
- ―
- Average Volume (3M)
- 817.82K
- Price to Earnings (P/E)
- -2.4
- Beta (1Y)
- 0.58
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 48
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Evommune, Inc. Business Overview & Revenue Model
Company Description
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical devel...
Evommune, Inc. Financial Statement Overview
Summary
Financials reflect a high-burn, pre-profit biotech profile. Income statement and cash flow are weak (TTM revenue at $0, very large net losses, and ~-$91M TTM free cash flow), partially offset by a much stronger balance sheet with low leverage (~$7.7M debt vs ~$251M equity) that improves financial flexibility.
Income Statement
18Very NegativeBalance Sheet
54NeutralCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 0 | 13.00M | 7.00M | 5.00M |
| Gross Profit | 0 | 13.00M | 5.71M | 4.00M |
| EBITDA | -120.66M | -79.68M | -65.49M | -32.99M |
| Net Income | -113.07M | -68.87M | -66.81M | -34.05M |
Balance Sheet | ||||
| Total Assets | 278.30M | 224.95M | 76.06M | 82.25M |
| Cash, Cash Equivalents and Short-Term Investments | 168.64M | 149.20M | 72.04M | 79.08M |
| Total Debt | 7.72M | 1.71M | 193.31M | 150.63M |
| Total Liabilities | 26.93M | 19.38M | 220.29M | 159.96M |
| Stockholders Equity | 251.37M | 205.57M | -144.24M | -77.71M |
Cash Flow | ||||
| Free Cash Flow | -91.00M | -76.68M | -58.28M | -30.09M |
| Operating Cash Flow | -90.40M | -76.44M | -58.20M | -29.97M |
| Investing Cash Flow | -163.64M | -115.31M | -3.99M | -48.43M |
| Financing Cash Flow | 274.58M | 220.76M | 49.42M | 63.75M |
Evommune, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EVMN, the sentiment is Positive. The current price of 8.02 is above the 20-day moving average (MA) of 6.23, above the 50-day MA of 7.65, and below the 200-day MA of 17.22, indicating a neutral trend. The MACD of 0.13 indicates Negative momentum. The RSI at 60.64 is Neutral, neither overbought nor oversold. The STOCH value of 83.25 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for EVMN.
Evommune, Inc. Risk Analysis
Evommune, Inc. disclosed 78 risk factors in its most recent earnings report. Evommune, Inc. reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
1 New RiskEvommune, Inc. Peers Comparison
Overall Rating
VIR72Outperform
ALT51Neutral- EVMN50Neutral
VALN49Neutral
ARCT47Neutral
OCGN47Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| VIR | 72Outperform | $2.25B | -9.70 | -21.38% | ― | 1695.96% | 65.40% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| ALT | 51Neutral | $375.42M | -2.31 | -29.26% | ― | 30.00% | 31.68% |
| EVMN | 50Neutral | $312.84M | -2.43 | -62.63% | ― | ― | ― |
| VALN | 49Neutral | $563.44M | -2.92 | -152.15% | ― | -21.91% | -134.63% |
| ARCT | 47Neutral | $268.34M | -2.77 | -46.79% | ― | -74.84% | -25.04% |
| OCGN | 47Neutral | $325.87M | -4.41 | 643.95% | ― | -11.01% | 8.03% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| EVMN | Evommune, Inc. | 8.02 | -11.43 | -58.77% | |
| ALT | Altimmune | 1.61 | -2.58 | -61.58% | |
| ARCT | Arcturus Therapeutics | 8.44 | 1.68 | 24.85% | |
| OCGN | Ocugen Inc | 0.87 | -0.29 | -24.74% | |
| VIR | Vir Biotechnology, Inc. | 12.12 | 6.63 | 120.77% | |
| VALN | Valneva Se | 5.76 | -3.13 | -35.21% |
Evommune, Inc. Corporate Events
Evommune Reports Third-Quarter Results and Pipeline Updates
NegativeOn November 12, 2026, Evommune reported third-quarter financial results and business updates. The company said its immunology pipeline included EVO301, EVO756, EVO570 and EVO646, targeting chronic inflammatory and autoimmune diseases through biologic...
Evommune Highlights EVO570 and Expanding Immunology Portfolio
NeutralOn November 5, 2026, Evommune announced a pre-recorded webcast on EVO570 and its expanding immunology portfolio. Management was set to discuss EVO570’s biology, preclinical profile, planned rheumatoid arthritis development path, transaction terms and...
Evommune Expands Autoimmune Pipeline Through License and Financing
PositiveOn November 4, 2026, Evommune entered an exclusive license agreement with Hinova Pharmaceuticals for worldwide rights outside Greater China to develop, manufacture and commercialize EVO570, an oral VAV1 molecular glue degrader. The consideration incl...
Evommune announces positive Phase 2a results for EVO301
PositiveOn October 1, 2026, Evommune reported Phase 2a proof-of-concept results for EVO301, a long-acting injectable fusion protein targeting IL-18, in a 70-patient trial for moderate-to-severe atopic dermatitis presented at the EADV 2026 Congress in Vienna....
Evommune Highlights Positive EVO301 Atopic Dermatitis Phase 2a Data
PositiveEvommune, Inc., a clinical-stage biotech developer of therapies for chronic inflammatory diseases, is advancing EVO301, a long-acting IL-18 binding protein fusion designed to neutralize aberrant IL-18 activity across multiple inflammatory pathways. T...
Evommune updates pipeline and market outlook in presentation
PositiveOn September 15, 2026, Evommune, Inc. posted an updated corporate presentation outlining progress across its pipeline of inflammatory disease therapies and the scale of its target markets. The deck emphasizes EVO301’s potential as a foundational IL‑1...
Evommune Shifts Atopic Dermatitis Focus to EVO301
NegativeOn September 8, 2026, Evommune reported top-line data from a randomized, double-blind, placebo-controlled Phase 2b trial of its oral MRGPRX2 antagonist EVO756 in 121 adults with moderate-to-severe atopic dermatitis. The 12-week study, with follow-up...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026